SCHEMBL4172969

SCHEMBL4172969

CC(C(=O)NC1C2CCC1N(Cc1ccccc1)C2)(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.43
CHRM1 P11229 2/20 0.43
CHRM3 P20309 2/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
ROCK2 O75116 1/20 0.43
ARHGDIA P52565 1/20 0.43
ROCK1 Q13464 1/20 0.43
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
AGTR2 P50052 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4174389 0.87 CHRM3 (0.49) CHRM2CHRM1CHRM3ROCK2ARHGDIA
SCHEMBL18423389 0.83 ROCK2 (0.49) ROCK2ARHGDIAROCK1KMT2ABRD4
SCHEMBL18423386 0.83 ROCK2 (0.49) ROCK2ARHGDIAROCK1KMT2ABRD4
SCHEMBL4177144 0.83 CHRM2 (0.60) CHRM2CHRM1CHRM3
SCHEMBL4186809 0.79 CHRM3 (0.46) CHRM2CHRM1CHRM3MEN1KMT2A
SCHEMBL4182174 0.77 CHRM3 (0.56) CHRM2CHRM1CHRM3CHRM4CHRM5
SCHEMBL6179367 0.76 ROCK2 (0.52) ROCK2ARHGDIAROCK1MAPT
SCHEMBL4189032 0.74 CHRM2 (0.55) CHRM2CHRM1CHRM3
SCHEMBL30316037 0.72 KMT2A (0.53) KMT2A
SCHEMBL23971248 0.71 KMT2A (0.55) CHRM2CHRM1CHRM3CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137623-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-28 US claimed
US-20090137623-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-28 US disclosed
EP-1968980-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES, LTD. (IN) 2008-09-17 EP disclosed
WO-2007110782-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137623-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM2, CHRM1, CHRM5 CHRM2 1/4885CHRM1 2/4885CHRM3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.